Objective The proposed Strep evaluates the potential of PlGF as a pharmaceutical for major chronic progressive cardiac disorders (ischemic heart disease, heart failure and arterial insufficiency (intermittent claudication and critical limb ischemia)) and as a biomarker for cardiovascular disease. The proposed Strep is based on: 1) basic research on the VEGF-signaling pathway (via PlGF) performed over the last five years (CTG, VIB-3); 2) prototype research performed with recombinant PlGF for pro-angiogenesis (GT and TG); and 3) basic research on the association of plasma PlGF and VEGF levels and human diseases (IGB) and 4) the development of a diagnostic test to evaluate PlGF as a biomarker for cardiovascular disease. The comprehensive strategy encompasses the validation of the "proof of concept" observations made by the academic parties of the consortium into therapeutic concepts in new relevant small animal models, development of industrial scale GLP/GMP quality materials and confirmation of their safety and efficacy in new, relevant large animal models. The strategy will be applied to the development of pro-angiogenic recombinant PlGF in ischemic heart disease models and in peripheral arterial insufficiency models. In parallel the value of PlGF as a predictive biomarker and as a diagnostic test for cardiovascular disease will be explored in a collaborative effort with a large diagnostic company. The principal aim of the project is to develop a new, safe and efficacious medicine to enhance the formation of blood vessels and in doing so, to develop new treatment paradigms for heart failure and limb ischemia. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosismedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesbasic medicinetoxicologymedical and health scienceshealth sciencesnutritionobesity Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) LSH-2005-2.1.1-10 - Research on cardiovascular disease with strong SME involvement Call for proposal FP6-2005-LIFESCIHEALTH-7 See other projects for this call Funding Scheme STREP - Specific Targeted Research Project Coordinator THROMBOGENICS N.V. EU contribution No data Address Gaston Geenslaan 1 HEVERLEE Belgium See on map Links Website Opens in new window Total cost No data Participants (7) Sort alphabetically Sort by EU Contribution Expand all Collapse all GEYMONAT SPA Italy EU contribution No data Address Via S. Anna 2 ANAGNI See on map Links Website Opens in new window Total cost No data EUROGENTEC S.A. Belgium EU contribution No data Address Liege Science Park rue Bois Saint-Jean,5 SERAING See on map Links Website Opens in new window Total cost No data KATHOLIEKE UNIVERSITEIT LEUVEN Belgium EU contribution No data Address Oude Markt 13 LEUVEN See on map Links Website Opens in new window Total cost No data UNIVERSITY OF THE FREE STATE South Africa EU contribution No data Address Nelson Mandela Drive 339(G1) BLOEMFONTEIN See on map Links Website Opens in new window Total cost No data ROCHE DIAGNOSTICS GMBH Germany EU contribution No data Address Sandhofer Strasse 116 MANNHEIM See on map Links Website Opens in new window Total cost No data CONSIGLIO NAZIONALE DELLE RICHERCHE Italy EU contribution No data Address Piazzale Aldo Moro 7 ROME See on map Links Website Opens in new window Total cost No data THROMBOGENICS LIMITED Ireland EU contribution No data Address 14 Bridgecourt Office Park, Walkinston avenue DUBLIN See on map Links Website Opens in new window Total cost No data
